Tier II Mutagenic Screening of 13 NIOSH Priority Compounds, Individual Compound Report, Hexachloro-1,3-Butadiene, Report No. 35.
NIOSH 1981 Jul:175 pages
The Tier II mutagenic screening of hexachloro-1,3-butadiene (87683) (HCBD) was conducted. The unscheduled DNA synthesis (UDS) assay was conducted with human embryonic intestinal cells, rat liver S9, and of rat bone marrow cells was performed after in vivo exposure to 10 or 50 parts per million (ppm) HCBD for 7 hours per day for 1 or 5 days. Dominant lethal tests were performed on male rats and sperm abnormality tests were conducted on male mice after in vivo exposure to 10 or 50ppm for 7 hours per day for 5 days. The sex linked recessive lethal test was performed with Drosophila-melanogaster after a 1 hour exposure to 25ppm HCBD. In the UDS assay, HCBD killed all cells at concentrations above 31 and 125 micrograms per milliliter with and without S9, respectively. No pattern was evident in the increased number of grains per nucleus at various concentrations. The only statistically significant increase in rat bone marrow cell DNA aberrations was observed in female rats exposed to a single dose of 10ppm HCBD. All mice exposed to 50ppm died. In those exposed to 10ppm, there were no increases in abnormal sperm frequency. There were no effects due to HCBD in rat pregnancies, implantations, or early deaths in the dominant lethal test. There was no increase in the sex linked recessive lethal mutation frequency in Drosophila-melanogaster. The author concludes that HCBD was not mutagenic under these test conditions.
NIOSH-Contract; Contract-210-78-0026; Screening-methods; Bioassays; Mutagenesis;
NTIS Accession No.
Inveresk Research International Limited, Musselburgh EH21 7UB, Scotland, NIOSH, Cincinnati, Ohio, 175 pages, 19 references